|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.30 USD | +0.52% |
|
+1.09% | +5.72% |
| 10:23am | After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway |  |
| 06-11 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Pfizer Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 331,440 | 287,626 | 162,560 | 150,345 | 141,574 | 149,154 | - | - |
| Change | - | -13.22% | -43.48% | -7.51% | -5.83% | 5.35% | - | - |
| Enterprise Value (EV) 1 | 338,807 | 300,723 | 221,758 | 194,219 | 192,773 | 197,431 | 191,230 | 187,049 |
| Change | - | -11.24% | -26.26% | -12.42% | -0.74% | 2.42% | -3.14% | -2.19% |
| P/E Ratio | 15.3x | 9.37x | 77.8x | 18.8x | 18.3x | 12.2x | 13x | 15.8x |
| PBR | 4.3x | 3x | 1.83x | 1.7x | 1.64x | 1.7x | 1.68x | 1.66x |
| PEG | - | 0.2x | -0.8x | 0x | -5.16x | 0.2x | -2.21x | -0.9x |
| Capitalization / Revenue | 4.08x | 2.87x | 2.78x | 2.36x | 2.26x | 2.42x | 2.51x | 2.7x |
| EV / Revenue | 4.17x | 3x | 3.79x | 3.05x | 3.08x | 3.2x | 3.22x | 3.38x |
| EV / EBITDA | 13.3x | 7.1x | 14.2x | 6.74x | 6.75x | 7.79x | 7.9x | 8.81x |
| EV / EBIT | 16.7x | 8.07x | 23.8x | 8.91x | 8.77x | 9.06x | 9.43x | 10.6x |
| EV / FCF | 11.3x | 11.6x | 46.3x | 19.7x | 21.2x | 10.1x | 10.8x | 11.7x |
| FCF Yield | 8.82% | 8.66% | 2.16% | 5.06% | 4.71% | 9.89% | 9.22% | 8.54% |
| Dividend per Share 2 | 1.56 | 1.61 | 1.65 | 1.68 | 1.72 | 1.752 | 1.745 | 1.747 |
| Rate of return | 2.64% | 3.14% | 5.73% | 6.33% | 6.91% | 6.7% | 6.67% | 6.68% |
| EPS 2 | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 | 2.138 | 2.012 | 1.657 |
| Distribution rate | 40.5% | 29.4% | 446% | 119% | 126% | 81.9% | 86.7% | 105% |
| Net sales 1 | 81,288 | 100,330 | 58,496 | 63,627 | 62,579 | 61,690 | 59,323 | 55,336 |
| EBITDA 1 | 25,426 | 42,336 | 15,590 | 28,801 | 28,563 | 25,344 | 24,194 | 21,226 |
| EBIT 1 | 20,235 | 37,272 | 9,300 | 21,788 | 21,971 | 21,781 | 20,284 | 17,628 |
| Net income 1 | 21,979 | 31,372 | 2,119 | 8,031 | 7,771 | 11,070 | 10,960 | 9,629 |
| Net Debt 1 | 7,367 | 13,097 | 59,198 | 43,874 | 51,199 | 48,277 | 42,076 | 37,895 |
| Reference price 2 | 59.05 | 51.24 | 28.79 | 26.53 | 24.90 | 26.17 | 26.17 | 26.17 |
| Nbr of stocks (in thousands) | 5,612,867 | 5,613,315 | 5,646,413 | 5,666,990 | 5,685,708 | 5,699,444 | - | - |
| Announcement Date | 08/02/22 | 31/01/23 | 30/01/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.24x | 3.2x | 7.79x | 6.7% | 149B | |
| 33.97x | 12.34x | 25.42x | 0.59% | 1,035B | |
| 25.47x | 5.87x | 15.96x | 2.24% | 574B | |
| 27.52x | 6.71x | 13.7x | 3.05% | 397B | |
| 17.45x | 4.31x | 10.59x | 3.08% | 324B | |
| 22.84x | 4.75x | 13.5x | 1.84% | 281B | |
| 21.11x | 5.44x | 13.22x | 2.98% | 278B | |
| 12.49x | 4.69x | 9.58x | 4.02% | 193B | |
| 23.02x | 6.15x | 10.74x | 2.85% | 191B | |
| -45.04x | 5.44x | 30.73x | 2.58% | 156B | |
| Average | 15.11x | 5.89x | 15.12x | 2.99% | 357.91B | |
| Weighted average by Cap. | 22.42x | 7.39x | 17.23x | 2.28% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PFE Stock
- Valuation Pfizer Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition